Nipocalimab Biosimilar - Research Grade

Human

FcRn

>1mg/ml

Human IgG1-Lambda2

Batoclimab Biosimilar - Research Grade (ICH5049), Rozanolixizumab Biosimilar - Research Grade (ICH5051), Efgartigimod Biosimilar - Research Grade (ICH5223), Orilanolimab Biosimilar - Research Grade (ICH5744)

https://www.imgt.org/mAb-DB/

ICH3002

P55899

2217

RRID:AB_2921592

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-FcRn antibody nipocalimab, supplied strictly for research use only. It is a fully recombinant human IgG1-lambda protein built around the same molecular target, the neonatal Fc receptor (FcRn, encoded by FCGRT, UniProt P55899), and is intended as a laboratory reagent rather than as the clinical drug. It is not for human or veterinary use. The analog is useful for researchers studying FcRn biology, IgG homeostasis, and antibody half-life engineering: it serves as a defined positive control in FcRn-binding and IgG-recycling assays, as a benchmarking or reference molecule in comparability and bioanalytical method development, and as a tool for probing the FcRn-IgG interaction in vitro. Because it is offered at research grade with low endotoxin levels and in bulk milligram-to-gram quantities, it supports higher-throughput screening, structure-function studies, and preclinical model work where consistent, well-characterized material is needed. Ultra-low-endotoxin options support endotoxin-sensitive cell-based and functional assays. FcRn (neonatal Fc receptor) is a non-classical MHC class I-like molecule composed of an FCGRT-encoded alpha chain (UniProt P55899) non-covalently associated with beta-2-microglobulin. It binds the Fc region of IgG and also albumin in a strictly pH-dependent manner: binding is tight in the acidic environment of the endosome (around pH 6) and released at near-neutral extracellular pH (around 7.4). Through this pH switch, FcRn rescues pinocytosed IgG and albumin from lysosomal degradation and recycles them back to the cell surface, extending their serum half-life. FcRn also mediates transcytosis of IgG across epithelial and placental barriers, contributing to maternal-to-fetal antibody transfer and mucosal immunity. Blocking the IgG-binding site on FcRn accelerates catabolism of circulating IgG, including pathogenic autoantibodies, which is the rationale behind FcRn-antagonist drug development.

IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor, IgG receptor FcRn large subunit p51, FCGRT

Detects human FcRn. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Nipocalimab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Nipocalimab (anti-FcRn) Biosimilar

Q: Is the Nipocalimab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Nipocalimab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Nipocalimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Nipocalimab that binds human FcRn.